Cardiol Therapeutics Reports 2025 AGM Results
Ticker: CRDL · Form: 6-K · Filed: May 29, 2025 · CIK: 1702123
Sentiment: neutral
Topics: shareholder-meeting, agm, corporate-governance
TL;DR
Cardiol Therapeutics filed its 2025 AGM results today, showing shareholder decisions.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on May 29, 2025, reporting the results of its 2025 Annual General Meeting of Shareholders. The filing includes a news release dated May 29, 2025, detailing these results. Cardiol Therapeutics Inc. is a Canadian company focused on biological products.
Why It Matters
Shareholder meeting results are crucial for understanding corporate governance and management's standing with investors.
Risk Assessment
Risk Level: low — This filing is a routine report of a shareholder meeting and does not contain new financial or operational risks.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- May 29, 2025 (date) — Filing date and news release date
FAQ
What type of company is Cardiol Therapeutics Inc.?
Cardiol Therapeutics Inc. is a company in the Biological Products sector, specifically SIC 2836.
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the results of Cardiol Therapeutics Inc.'s 2025 Annual General Meeting of Shareholders.
What is the filing date of this report?
The filing date is May 29, 2025.
Where is Cardiol Therapeutics Inc. headquartered?
Cardiol Therapeutics Inc. is headquartered at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada.
What exhibit is included with this filing?
Exhibit 99.1 is included, which is a News Release dated May 29, 2025, reporting the results of the 2025 Annual General Meeting of Shareholders.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 29, 2025 regarding Cardiol Therapeutics Inc. (CRDL).